Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Yokogawa Fluid Imaging Technologies provides industry-leading flow imaging microscopy solutions for rapid particle analysis. Their flagship product line—FlowCam—enables high-resolution digital imaging of subvisible particles to support safety and efficacy testing of biotherapeutic drugs, environmental water quality assessment, and advanced materials research. The company’s technologies are widely adopted by pharmaceutical companies for orthogonal subvisible particle analysis per USP <1788>, supporting regulatory compliance in parenteral drug formulation development[1][2][9].
No clinical results apply as the company does not develop therapeutics.
Products are deployed globally across more than fifty countries[1].
Notable recent innovation includes the integration of AI-assisted image analysis to automate identification/classification tasks.
In April 2020, the company was acquired by Yokogawa Electric Corporation to expand its life science instrumentation portfolio[4].
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Yokogawa Fluid Imaging Technologies.